TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05908110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication Message
Description: The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
Study: NCT05637879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir/pibrentasvir
Description: Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded, inactive pill equal in appearance to active study drug
Study: NCT06451848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab Injection (T, Solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab Injection (T, Solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
Study: NCT06134505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of olive oil in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study: NCT06337032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablet administered orally
Study: NCT05379127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-empowered follow up
Description: The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
Study: NCT06337032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose TOS)
Description: 15/60/7.52 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose TOS)
Description: 15/60/7.52 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose TOS)
Description: 15/60/7.52 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose TOS)
Description: 7.5/30/3.76 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose TOS)
Description: 7.5/30/3.76 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Lowest Dose TOS)
Description: 3.76/15/1.88 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Lowest Dose TOS)
Description: 3.76/15/1.88 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd ARV Agent
Description: A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd ARV Agent
Description: A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
Study: NCT05409404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + hot water immersion
Description: Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise + thermoneutral water immersion
Description: Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
Study: NCT06337032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
Description: NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Administered according to the prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: Administered according to the prescribing information

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir Boosted with ritonavir (LPV/r)
Description: Administered according to the prescribing information
Study: NCT05434078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthofeet Shoes
Description: Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
Study: NCT06252584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccines, Peptide
Description: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
Study: NCT05507333

Intervention type: DEVICE
Group type: OTHER
Intervention: Gedea pessary
Description: Daily administration of the Gedea pessary during 6 days
Study: NCT05982678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
Study: NCT05829265

Intervention type: BEHAVIORAL
Intervention: A digital social intervention by primary care clinicians.
Description: The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs).
Study: NCT05487599

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: • LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
Study: NCT06276335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and guided bone regeneration (Test)
Description: In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late implant placement and guided bone regeneration (Control)
Description: A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
Study: NCT06471010

Intervention type: OTHER
Intervention: Blended Dynamic Interpersonal Therapy (B-DIT)
Description: The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
Study: NCT04110132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglion impar block with Bupivacaine.
Description: Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
Study: NCT06451848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection (R, Powder for solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for Injection (R, Powder for solution for injection)
Description: A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
Study: NCT06332859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
Study: NCT04893707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.
Study: NCT06018454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout on PGT-A
Description: Educational handout on PGT-A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout on PGT-A
Description: Educational handout on PGT-A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout on PGT-A and genetic counseling
Description: Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
Study: NCT05098132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: platinum chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: platinum chemotherapy
Study: NCT05287087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Symptoms 1 (MySt-1)
Description: The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Symptoms 2 (MySt-2)
Description: The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation.
Study: NCT04556916

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation.
Study: NCT04110132

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion impar block with normal saline
Description: Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
Study: NCT04441138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
Study: NCT05000788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
Study: NCT05018507

Intervention type: OTHER
Intervention: Data collection only
Description: No intervention, just data collection from system machines
Study: NCT06346132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality application
Description: In this group, virtual reality will be added to usual care
Study: NCT05462496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Pre-treatment tumor biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
Study: NCT04753307

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory measurements
Description: Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
Study: NCT05345860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ TNBC patients
Description: Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ HER2+ patients
Description: Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for high risk or MRD+ ER+ patients
Description: Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- TNBC patients
Description: Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- HER2+ patients
Description: Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The MRD strategy for low risk and MRD- ER+ patients
Description: Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice.